과제정보
This study was supported by the National Research Foundation of Korea funded by Korea government (MSIP) (Grant No.2018R1A5A2025272)
참고문헌
- Shin MK. Clinical herbology. Seoul:Younglimsa. 1997:322-3.
- Park BR, Lee SH, Han KM, Hwang JW, Kim HI, Baek SY. Development and Utilization of KASP Markers for the Identification of Three Types of Ephedra Herbs. Kor. J. Pharmacogn. 2022;53(4):226-33.
- Lee GS. The Anatomical Identification-key of Ephedrae Herba and its adulterant. Kor. J. Herbol. 2019;34(6):25-32.
- Ha TH, Kwon TW, Kim YK. Effects of Ephedra Herba ethyl-acetate fraction on high fat diet induced hyperlipidemic mice. Journal of Society of Preventive Korean Medicine 2014;18(2):101-13.
- Kim HJ, Kim EJ, Han YH. The Effect of Ephedra sinica Pharmacopuncture on Lipid Metabolism in an Experimental Mouse Model of Obesity. J. Int. Korean Med. 2016;37(4):579-90.
- Jeong JJ, Kim BW. The Effect of Ephedrae Herba Pharmacopuncture on Adipocyte Metabolism. Korean J. Orient. int. Med. 2008;29(1):80-9.
- Won CW, Jung YS, Yoon KH, Lee HY, Yoon MC, Kim BK, Park SD, Shin SS. Herba Ephedrae and Rhizoma Amorphophalli modulates visceral obesity in micro-CT of high fat induced obese male mice. Herb. Formula Sci. 2008;16(2):205-17.
- Oh MJ, Lee CH, Kim HJ, Kim HR, Kim MS, Lee DY, Oh CH, Kim MS, Kim JS. The comparative studies on anti-obesity effects of Ephedrae Herba and Cyperi rhizoma in high fat diet fed mice. Herb. Formula Sci. 2016;24(2):108-23.
- Jo EH, Jo IJ, Park SJ, Jo SH, Park MC. Effects of Ephedra sinica (ES) Extract on the Ovalbumin-Induced Allergid Asthma in Mice. J Korean Med Ophthalmol Otolaryngol Dermatol. 2014;27(3):84-95.
- Ryu HC, Shin JG. A study on proper dosage of Ma-huang. J of KMediACS. 2013;5(1):101-11.
- Lee TH, Hsing LC, Yang CS, Kim LH, Seo ES, Jang IS. Adverse Effects of Ephedra According to Sasang Typology in Healthy Adults : A Double-Blind Randomized Controlled Trial. Korean J. Orient. Int. Med. 2009;30(1):144-52.
- Kim JR, Yun SJ, Lee YK, Lee HJ, Kim JS. A Review on Safety of Herbal Medicines for Doping. J Korean Med. 2019;40(3):139-76.
- Jo GW, Ok JM, Kim SY, Lim YW. Review on the Efficacy and Safety of Mahuang and Ephedrine in the Treatment of Obesity -Focused on RCT-. J Korean Med. 2017;38(3):170-84.
- Chang MS, Shim KJ, Oh JH, Yoon JW, Choi MJ, Kim DR, Yang WM, Lim HH, Lee MJ, Park SK. Acute Oral Toxicity of Ephedrae Herba in SD Rats. Korean J. Oriental Physiology & Pathology. 2008;22(4):762-75.
- Choi DG, Shim KJ, Choi BJ, Park SY, Chang MS, Park SK. Subacute Oral Toxicity of Ephedrae Herba Extract in SD Rats. Kor. J. Herbology 2008;23(4):1-7.
- Yoo JH, Park SM, Jung DH, Kim SC. Ephedra has anti-fibrogenic effects by inhibiting the TGFβ/Smad pathway in LX-2 cells. Herb. Formula Sci. 2024;32(2):141-53.
- Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Ann Med. 2022;54(1):1548-60.
- Zhao XA, Chen GM, Liu Y, Chen YX, Wu HY, Chen J, Xiong YL, Tian C, Wang GY, Jia B, Xia J, Wang J, Yan XM, Zhang ZP, Huang R, Wu C. Inhibitory effect of silymarin on CCl(4)-induced liver fibrosis by reducing Ly6C(hi) monocytes infiltration. Int J Clin Exp Pathol. 2017;10(12):11941-51.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63.
- Gillessen A, Schmidt HH. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther. 2020;37(4):1279-301.
- Balta C, Herman H, Boldura OM, Gasca I, Rosu M, Ardelean A, Hermenean A. Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-beta/Smad signaling pathway. Chem Biol Interact. 2015;240:94-101.
- Bai Y, Wang L, TingYang, Wang L, Ge W. Silymarin ameliorates peritoneal fibrosis by inhibiting the TGF-beta/Smad signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(10):2379-91
- Eraky SM, El-Mesery M, El-Karef A, Eissa LA, El-Gayar AM. Silymarin and caffeine combination ameliorates experimentally-induced hepatic fibrosis through down-regulation of LPAR1 expression. Biomed Pharmacother. 2018;101:49-57.
- Sokar SS, El-Sayad ME, Ghoneim ME, Shebl AM. Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats. Biomed Pharmacother. 2017;89:98-107.
- Okda TM, Abd-Alhaseeb MM, Barka K, Ragab NM. Ginger potentiates the effects of silymarin on liver fibrosis induced by CCL4: the role of galectin-8. Eur Rev Med Pharmacol Sci. 2019;23(2):885-91.
- Lee JA, Shin MR, Choi J, Kim M, Park HJ, Roh SS. Co-Treatments of Gardeniae Fructus and Silymarin Ameliorates Excessive Oxidative Stress-Driven Liver Fibrosis by Regulation of Hepatic Sirtuin1 Activities Using Thioacetamide-Induced Mice Model. Antioxidants (Basel). 2022;12(1):97.
- Kim WH, Choi DY. Jangbubyeonjeungnonchi <7th Ed>. Seoul:Seongbosa. 2004:153-166.
- Byun SH, Park SM, Kim SC, Cho IJ. Anti-fibrotic Effect of Mori Folium Extract in Hepatic Stellate Cells. Kor. J. Herbology. 2013;28(4):49-55.
- Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. TGF-β1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci. 2001;114:3905-14
- Allen RR, Higgins PJ. Plasminogen activator inhibitor type-1 expression and the pathophysiology of TGF-β1-induced epithelial-to-mesenchymal transition. Recent Res Devel Physiol. 2004;2:355-66.
- Desmouliere A, Geiniz A, Gabbiani F, Gabbiani G. Transforming growth factor-β1 induces α-Smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103-11.
- Chung JY, Chan MK, Li JS, Chan AS, Tang PC, Leung K, To K, Lan H, Tang PM. TGF-β Signaling: From Tissue Fibrosis to Tumor Microenvironment. Int J Mol Sci. 2021;22(14):7575.
- Lee SI. Herbology. Seoul:Suseowon. 1981:189-90.
- Zhai HQ, Zhang SF, Gao MC, Liu Y, Ou M, Meng FY, Wang YY. Effects of Herba Ephedra Sinicae and Fructus Schisandrae Chinensis on pathology of rats with bleomycin A(5)-induced idiopathic pulmonary fibrosis. Zhong Xi Yi Jie He Xue Bao. 2011;9(5):553-7.
- Kim KH, Kang GH, Lee YU, Kang S, Ji SH, Song JH, Kim CH, Lee SK. Treating COVID-19 with Qingfei Paidu Decoction with and without Ephedra Herba: A Retrospective Case Series. J. Int. Korean Med. 2022;43(2):264-73.
- Yoon KH, Lee HY, Jung YS, Seo BI, Park GY, Yoon MC, Shin SS. Modulation of obesity by Gyeongshingangjeehwan18 in ob/ob mice. Kor. J. Herbology 2010;25(3):1-9.
- Lee HY, Yoon KH, Seo BI, Park GY, Yoon MC, Shen ZB, Cui HH, Shin SS, Molecular biologic mechanism of obesity by GGEx18. Kor. J. Herbology 2011; 26(1):65-74.
- Kim HJ, Kim JB. Effects of Mahwangimun-tang in Cholesterol Diet and Triton WR-1339-induced Hyperlipidemic Rat. Korean J. Oriental Physiology & Pathology. 2010;24(1):102-10.
- Ki YB, Kim DH, Kang DH, Kim SJ, Choi JB, Yang MS. Effect of Mixed Extract of Ephedrae Sinica and Fibrosum Gypsum on Differentiation of Preadipocytes and Obesity of Rats. Journal of Korean Medicine Rehabilitation. 2014;24(3):11-27.
- Kang HJ, Ku TH, Kim GC. Hemodynamic Effects of Herbal Prescription Containing Ephedra on Weight Loss: A 3-Dimensional Radial Pulse Tonometry Device Study. J Korean Med Obes Res. 2023;23(1):28-41.
- Park JE, Hwang HS, Kim TY. Studies on Anti-inflammatory Effects of Mahwanghangingamchosukgo-tang Extracts. Korean J. Oriental Physiology & Pathology. 2020;34(6):319-25.
- Jang HK, Heo DS. Anti-OsteoArthritic effects of Mahwangbuja-tang(Mahuangfuzi-tang) on Papain-Induced Osteo Arthritic mice model. J Oriental Rehab Med. 2012;22(4):59-77.
- Bae JY, Jo EH, Kim HY, Park MC. Inhibitory Effect of Ten Kinds of Herbal Medicine Including Ephedrae Herba on Nitric Oxide in LPS-induced Murine Peritoneal Macrophage. The Journal of Korean Oriental Medical Ophthalmology & Otolaryngology & Dermatology. 2009;22(2):19-38.
- Wang H, Sun R, Yang S, Ma X, Yu C. Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review. Front Med (Lausanne). 2022;9:934989.
- Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-61.
- Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
- Fabregat I, Caballero-Diaz D. Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. Front Oncol. 2018;8:357.
- Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181-94.
- Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;3: 1473-92.
- Ren Y, Chen Y, Tang EH, Hu Y, Niu B, Liang H, Xi C, Zhao F, Cao Z. Arbidol attenuates liver fibrosis and activation of hepatic stellate cells by blocking TGF-beta1 signaling. Eur J Pharmacol. 2024;967:176367.
- Huang SJ, Chen SQ, Lin Y, Yang HY, Ran J, Yan FF, Huang M, Liu XL, Hong LC, Zhang XD. Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K/Akt signaling in adult offspring mice. Liver Int. 2021;41(8):1867-78.
- Dewidar B, Meyer C, Dooley S, Meindl-Beinker N. TGF-in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells. 2019;8(11):1419.
- Chen G, Xia B, Fu Q, Huang X, Wang F, Chen Z, Lv Y. Matrix Mechanics as Regulatory Factors and Therapeutic Targets in Hepatic Fibrosis. Int J Biol Sci. 2019;15(12):2509-21.